Incyte said it recorded net income of $106.5 million ($0.54 diluted per share) for the 3 months ended September 30, 2024, and a net loss of $168.6 million ($0.80 per share) for the 9 months. In the same period of 2023, net income was $171.3 million for the 3 months and $396.5 million for the 9 months.

1. 01

   Incyte said it recorded net income of $106.5 million ($0.54 diluted per share) for the 3 months ended September 30, 2024, and a net loss of $168.6 million ($0.80 per share) for the 9 months. In the same period of 2023, net income was $171.3 million for the 3 months and $396.5 million for the 9 months.

2. 02

   Incyte said the increase in JAKAFI net product revenues was driven by a volume increase of $78.2 million and a price increase of $26.7 million for the 3 months, and a volume increase of $74.8 million and a price increase of $45.6 million for the 9 months. The company cited an increase in paid demand across all indications as the main factor.

3. 03

   The company said research and development expenses for the 9 months ended 2024 included $679.4 million of expense related to in-process research and development assets acquired in the Escient acquisition. It also recognized compensation expense of about $11.3 million in research and development and about $20.2 million in selling, general and administrative expenses for accelerated vesting of Escient stock awards in Q2.

4. 04

   Incyte said it used net cash of $45.9 million in operating activities in the 9 months ended 2024, compared with net cash provided of $348.8 million in the prior-year period. It said net cash used in financing activities was $2.0 billion, mainly for share repurchases of $2.0 billion. As of September 30, 2024, cash, cash equivalents and marketable securities totaled $1.8 billion.

Key figures

Quarter ended September 30, 2024

Revenue

$1.1B

Operating income

$146M

Net income

$106M

EPS

$0.54

Analysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.